Original Research Article

**Primula vulgaris** extract induces cell cycle arrest and apoptosis in human cervix cancer cells

Selim Demir a,*, Ibrahim Turan b, Rezzan Aliyazicioglu c, Serap Ozer Yaman d, Yusuf Aliyazicioglu d

a Department of Nutrition and Dietetics, Faculty of Health Sciences, Karadeniz Technical University, 61080 Trabzon, Turkey
b Department of Genetic and Bioengineering, Faculty of Engineering and Natural Sciences, Gumushane University, 29100 Gumushane, Turkey
c Department of Biochemistry, Faculty of Pharmacy, Karadeniz Technical University, 61080 Trabzon, Turkey
d Department of Medical Biochemistry, Faculty of Medicine, Karadeniz Technical University, 61080 Trabzon, Turkey

**Abstract**

**Primula vulgaris** belongs to the genus *Primula*, members of which are frequently used in folk medicine. Various studies have investigated the cytotoxic effect of different *Primula* species, but there have been limited studies on the cytotoxic effect of *P. vulgaris*. The aim of this study was to investigate the cytotoxic effects, and possible mechanisms involved, of *P. vulgaris* flower extract on human cervical cancer (HeLa) cells. The cytotoxic effect of the extract on HeLa cells was revealed using the MTT assay. Mechanisms involved in the extract's cytotoxic effect were then investigated in terms of apoptosis, mitochondrial membrane potential, and the cell cycle, using fluorometric methods. *P. vulgaris* flower extract exhibited selective cytotoxic effects against HeLa cells by arresting their cell cycle at the S phase, and inducing the number of apoptotic cells compared to normal fibroblast cells by reducing mitochondrial membrane potential in a concentration-dependent manner. This is the first study to reveal the antiproliferative effect of *P. vulgaris* flower extract. Further studies are now needed to identify the cytotoxic molecules in the extract and their mechanisms.

© 2018 Xi’an Jiaotong University. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Cancer is a global health problem, and 21% and 9% of deaths in developed and developing countries, respectively, are reported to be cancer-related. The World Health Organization (WHO) predicts approximately 27 million new cases of cancer and 17.5 million deaths from cancer annually by 2050 [1]. Cervical cancer is the second most common cancer type in women worldwide, and failure to detect the condition at an early stage and/or the development of treatment resistance can lead to fatal outcomes [2]. While the treatment of many cancer patients often involves the use of chemotherapy and radiotherapy, these treatments gradually cause damage to normal cells, and resistance to targeted cancer cells reduces the success rate of these therapies [3]. Current research therefore focuses on developing new generation drugs with fewer side-effects [4].

Plants have been used to treat and prevent many human and animal diseases since ancient times. Today, approximately 50% of the anticancer drugs used in chemotherapy are obtained from plants. According to the WHO data, more than 80% of people living in developing countries use natural products for primary health problems. Recent surveys show that more than 60% of cancer patients use natural products for therapeutic purposes. However, very few of these medicinal plants have been scientifically evaluated in terms of their anticancer properties. The idea of producing new generation anticancer drugs from natural products has therefore attracted great interest in both the scientific and commercial spheres in recent years [4–6]. *Primula* belongs to the family *Primulaceae*, and more than 400 species are found in the Northern hemisphere, growing in moist and temperate climatic regions [7]. *Primula* species are used in traditional medicine against bronchitis, asthma, and insomnia [6]. *Primula* species are reported to be rich in saponins, alkaloids, tannins, terpenes, and phenolic compounds [7,8]. The antioxidant, antimicrobial, antigenotoxic, anti-inflammatory, hypoglycemic, cytotoxic, and wound healing properties of *Primula* species have been extensively studied, and these useful biological properties are attributed to the presence of the above-mentioned compounds [6–10]. Commercial interest in *Primula* species is growing all the time, especially in the food, cosmetic, and drug industries, due to their beneficial biological properties [6].

Numerous studies have investigated the antiproliferative effect of different *Primula* species. The cytotoxic effect of aqueous

---

**Peer review under responsibility of Xi'an Jiaotong University.**

*Corresponding author.

E-mail address: selim-demir@hotmail.com (S. Demir).

https://doi.org/10.1016/j.jpha.2018.05.003

2095-1779/© 2018 Xi'an Jiaotong University. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
extracts of *P. vulgaris* flowers and leaves was examined using the brine shrimp method, and LC₅₀ values of 311 and 40 μg/mL were determined respectively, in one study [11]. Behzad et al. [3] showed that the methanol extract of *Primula auriculata* exhibits apoptotic properties via caspase activation in the human colon cancer (HT-29) cell line. However, no previous studies have investigated the cytotoxic effect of *P. vulgaris* flower extract on cervical cancer cells. The aim of this study was to investigate the cytotoxic effect of *P. vulgaris* flower extract on HeLa cells, together with the mechanism involved.

2. Experimental

2.1. Chemicals and reagents

Gentamicin and trypsin/EDTA solutions were obtained from Biological Industries (Kibbutz Beit Haemek, Israel), Eagle’s minimum essential medium (EMEM) from Lonza (Verviers, Belgium), and fetal bovine serum (FBS) from Biochrom (Berlin, Germany). All flow cytometry kits were purchased from Becton Dickinson (San Diego, CA, USA). The other principal chemicals used were obtained from Sigma (St. Louis, MO, USA).

2.2. Sample collection and extract preparation

*P. vulgaris* plant samples used in the study were collected from Trabzon, Türkiye in the Spring of 2015. The plant samples were dried at room temperature for 20 days. The flower parts were then carefully separated and converted into a fine powder using a blender and milling procedures. Next, 0.5 g of the powdered samples was mixed with 10 mL of dimethyl sulfoxide (DMSO). After thorough vortexing, the mixture was left to incubate for 24 h for continuous shaking at 150 rpm at 45 °C. After incubation, the mixture was centrifuged at 2000 g for 10 min. The supernatant was filtered with Whatman No. 1 filter paper and then passed through 0.2 μm filters. The resulting DMSO extract of *P. vulgaris* flower was aliquoted for use in experiments and stored in the dark at −20 °C.

2.3. Drug preparation and treatment

Cisplatin was dissolved in DMSO and used as a reference compound in cytotoxicity experiments due to its use in cervical cancer treatment [12]. Final solvent concentrations of compounds were no higher than 0.5% in culture media in any experiment. That concentration was not sufficient to affect cell morphology or viability.

2.4. Cell culture

Human cervix adenocarcinoma (HeLa, ATCC-CCL-2) cancer and human normal foreskin fibroblast (ATCC-CRL-2522) cells were supplied by the American Type Culture Collection (Manassas, VA, USA). Both cells were cultured in EMEM supplemented with 10% heat inactivated FBS and 1% gentamicin solution with a 5% CO₂ supply at 37 °C.

2.4.1. Cytotoxicity experiments

MTT assay with a 72 h treatment time was employed to measure the cytotoxic effects of *P. vulgaris* flower extract and cisplatin on human cervical cancer and normal fibroblast cells [13,14]. Briefly, HeLa and fibroblast cells were seeded into flat-bottomed 96-well cell culture plates at 1 × 10⁴ and 2 × 10³ cells per well, respectively. The cells were then treated with varying concentrations of *P. vulgaris* flower extract (0–500 μg/mL) and cisplatin (0–10 μg/mL) for 72 h in a triplicate manner. Subsequently, 10 μL of MTT dye (0.25 mg/mL) was placed inside each well. The crystals that emerged were then dissolved in DMSO. Finally, absorbance was measured at 570 nm with a microplate reader (Molecular Devices Versamax, California, USA). Optical densities were employed to calculate percentage viabilities in treated cells compared to untreated control cells. Log-concentrations versus % cell viabilities were plotted with a logarithmic graph, which was then used to determine the IC₅₀ values. The IC₅₀ values of the extract and cisplatin in the both cell lines were used to elicit a selectivity index [5] with the following formula:

Selectivity Index = Fibroblast cells IC₅₀/HeLa cells IC₅₀

2.4.2. Cell cycle analysis

Cell cycle analysis was performed using a commercial kit (BD CycleTest™ Plus, Cat No: 340422, San Diego, CA, USA) following the manufacturer’s recommendations. HeLa cells were treated with 90, 180, and 270 μg/mL concentrations of *P. vulgaris* flower extract for 72 h, then harvested, and washed twice with buffer solution. The cells were incubated with trypsin solution for 10 min followed by trypsin inhibitor and RNase solution for 10 min. Finally, the cells were further treated with propidium iodide (PI) staining on ice for 10 min. Data from 30,000 cells per sample were collected and analyzed on a flow cytometer (BD Accuri C6, MI, USA). The percentage of the cells in cycle phases was determined using MODFIT 3.0 verity software. The results were finally compared with the untreated negative control cells.

2.4.3. Apoptosis analysis

Apoptosis analysis was performed using a commercial kit (BD Pharmingen™, Cat No: 559763, San Diego, CA, USA) following the manufacturer’s recommendations. HeLa cells were treated with 90, 180, and 270 μg/mL concentrations of *P. vulgaris* flower extract for 72 h, then harvested, and washed twice with ice-cold phosphate-buffered saline solution. The cells were then resuspended with the binding buffer. Next, they were incubated with PE-Anexin V and 7-AAD for 10 min at room temperature in the dark. Data from 10,000 cells per sample were collected and analyzed on a flow cytometer (BD Accuri C6, MI, USA). The results were compared with the untreated negative control cells.

2.4.4. Mitochondrial membrane potential (MMP) analysis

3′,3′-dihexyloxacarbocyanine iodide DiOC₆(3) was used to determine the changes in MMP in this study. Normally, this tends to remain in the mitochondria. The decrease in the intensity of this dye is indicative of a decrease in MMP [15]. Cells were seeded into a flat-bottomed 96-well black-walled plate at 1 × 10³ cells per well. The cells were then treated with different concentrations of *P. vulgaris* flower extract (90–270 μg/mL) for 72 h. After treatment, the cells were washed with phosphate-buffered saline solution and loaded with 10 nM DiOC₆(3) for 30 min at 37 °C in the dark. Finally, fluorescence measurement was performed on a plate-reading fluorometer (Molecular Devices SpectraMax Paradigm Multi-Mode, Sunnyvale, CA, USA) with an excitation wavelength of 484 nm and an emission wavelength of 525 nm. Results are given as relative MMP compared to untreated negative control cells.

2.5. Statistical analysis

All experiments were performed at least three times, the results being expressed as mean ± standard deviation. Normal distribution was determined using the Kolmogorov-Smirnov test. One-Way ANOVA was used to analyze intergroup differences and
Tukey’s test was performed for post-hoc comparisons. \( p < 0.05 \) was regarded as significant.

3. Results

*P. vulgaris* flower extract exhibited selective cytotoxic effects on the HeLa cells compared to normal fibroblast cells. The IC\(_{50}\) value of the extract in HeLa cells was 182.4 \( \mu \)g/mL, while the IC\(_{50}\) value of the extract in fibroblast cells was calculated as 493.9 \( \mu \)g/mL (Fig. 1 and Table 1).

The results of the cell cycle analysis are presented in Fig. 2. All the concentrations of *P. vulgaris* flower extract significantly reduced the cell number at the G\(_2\)/M phase \( (p = 0.0001) \). Additionally, 180 and 270 \( \mu \)g/mL extract concentrations significantly reduced the cell number at the G\(_1\) phase and increased the cell number at the S phase compared to the untreated cells \( (p = 0.0001) \).

The results of the apoptosis analysis are presented in Fig. 3. *P. vulgaris* flower extract significantly reduced the number of viable cells and increased the numbers of apoptotic cells compared to untreated cells \( (p < 0.05) \).

MMP analysis results are presented in Fig. 4. The 180 and 270 \( \mu \)g/mL extract concentrations significantly reduced the MMP in HeLa cells \( (p = 0.001) \). The percentage reductions in MMP caused by *P. vulgaris* flower extract at concentrations of 90, 180, and 270 \( \mu \)g/mL were 8\%, 64\%, and 72\%, respectively.

4. Discussion

Cancer is one of the most important causes of disease-related mortality in the world. The WHO reports that between 2005 and 2015 approximately 84 million people lost their lives due to cancer [3]. Chemotherapy is frequently used in cancer treatment, but the toxic effects that occur over time limit the use of these drugs. Both the high mortality rate in cancer cases and the serious side-effects of chemotherapy and radiotherapy have encouraged the search for alternative and/or complementary treatments [4,5]. Natural products are today regarded as potential raw materials for new drug discoveries, and phenolic compounds found in natural products are particularly significant in this context due to their structures and activities. Investigation of the anticancer effects of both natural product extracts and compounds isolated from such products has become one of the popular research fields in recent years. Various criteria need to be met for an effective and acceptable anticancer agent, including its effects on normal cells being harmless [5,15]. We therefore planned cytotoxicity experiments in HeLa cells coupled with human normal foreskin fibroblast cells.

![Fig. 1](image1.png)  
**Fig. 1.** Effects of different concentrations of *P. vulgaris* flower extract on cell viability during a 72 h incubation period \( (n=3) \). There was a statistically significant decrease compared to normal fibroblast cells.

| Test compound             | IC\(_{50}\) (\( \mu \)g/mL) | Selectivity index |
|---------------------------|-------------------------------|-------------------|
| *P. vulgaris* flower extract | 182.4 ± 5.5                  | 2.1               |
| Cisplatin                 | 0.73 ± 0.05                   | 6.7               |

Table 1: Cytotoxic effects (IC\(_{50}\), \( \mu \)g/mL) and selectivity index of the test compounds.

![Fig. 2](image2.png)  
**Fig. 2.** Cell cycle analysis of *P. vulgaris* flower extract-treated HeLa cells after 72 h \( (n=6) \). Represents significant result \( (p < 0.05) \) compared with untreated cells.

![Fig. 3](image3.png)  
**Fig. 3.** Apoptosis analysis of *P. vulgaris* flower extract-treated HeLa cells after 72 h \( (n=4) \). Represents significant result \( (p < 0.05) \) compared with untreated cells.

![Fig. 4](image4.png)  
**Fig. 4.** Effects of *P. vulgaris* flower extract on the integrity of the mitochondrial membrane of HeLa cells after 72 h \( (n=3) \). Represents significant result \( (p < 0.05) \) compared with untreated cells.

Numerous methods, such as trypan blue, MTT assay, neutral red, and lactate dehydrogenase, are frequently used for the determination of cell viability, proliferation rates, and cytotoxicity. In order to determine the cytotoxic effect of the extract, we employ the
MTT, a reliable, sensitive, quantitative, and colorimetric method, previously used in similar studies [5,14,15]. P. vulgaris flower extract exhibited selective toxicity (2.7-fold) against HeLa cells compared to normal fibroblast cells. Deterioration of cell cycle control and decreased apoptosis are two of the characteristic features of cancer cells. Anticancer activity studies investigating novel agents therefore focus on the ability to halt the cell cycle and increase apoptosis [5,15,16]. We therefore investigated the mechanism involved in the cytotoxic effect of the extract on HeLa cells in terms of the cell cycle, MMP, and apoptosis using fluoro-metric methods. Our results show that P. vulgaris flower extract exhibited antiproliferative features in HeLa cells by stopping the cell cycle in the S phase and inducing apoptosis by reducing mitochondrial membrane potential in a concentration-dependent manner. Other studies involving the cytotoxic effect of Primula species have examined the cytotoxic effect of the ethanolic crude extract of Primula macrophylla and its ethyl acetate, chloroform, and benzene fractions using brine shrimp methods, with the most effective cytotoxic activity being observed in the crude extract [17]. Behzad et al. reported that the methanol extract of Primula auriculata exhibited a selective cytotoxic effect on human breast (MCF-7), liver (HepG2), and HT-29 cancer cell lines compared to normal bovine kidney cells. No cytotoxic effect was observed in that study in the human lung (A549) cancer cell line up to an extract concentration of 100 μg/mL [18]. Turan et al. [6] demonstrated that P. vulgaris leaf extract exhibits selective cytotoxic effects against human A549, HepG2, MCF-7, prostate (PC-3), and colon (WiDr) cancer cell lines compared to human normal fibroblast cells. Few studies have examined the cytotoxic activity of Primula species. However, the methanolic extract of Dionysia termoena, a member of the Primulaceae family, has been reported to exhibit cytotoxic effects in human myelogenous leukemia (K562), T-lymphocytic leukemia (Jurkat), bladder (Fen), and A549 cell lines in a dose-dependent manner. That study also determined that the cytotoxic effect of the extract in blood-derived cell lines (K562 and Jurkat) was derived from induced apoptosis [19]. Another study showed that the aqueous extract of Lysimachia vulgaris, a member of the Primulaceae family, and its hexane, dichloromethane, and methanol fractions had no cytotoxic effect on the MCF-7 and HepG2 cell lines up to a concentration of 200 μg/mL [20]. Studies have also investigated the antiproliferative activity of various compounds isolated from Primula species. Tokalov et al. [21] reported that isolated compounds isolated from Primula denticulata, such as 5-hydroxyflavone, 2′-hydroxyflavone, 5,2′-dihydroxyflavone, and 5,8-dihydroxyflavone, exhibit antiproliferative effects in the human acute myeloid leukemia (HL-60) cell line by activating cell cycle arrest and apoptosis.

Polyphenols are an important class of secondary herbal metabolites reported to exhibit strong antioxidant properties [6]. Recent studies in particular have reported that polyphenols can prevent the proliferation of cancer cells by activating cell cycle arrest, apoptosis, and cell signalization [22]. Primula species have been shown to be rich in phenolic compounds, such as kaempferol, quercetin, rutin, 5-hydroxy pyrogallol, apigenin, catechin derivatives, gallic acid, rosmarinic acid, p-coumaric acid, protocatechuic acid, p-OH benzoic acid, vanillic acid, caffeic acid, ferulic acid, and ellagic acid [7,8]. In our previous study, we demonstrated that the major components of P. vulgaris are as follows: p-coumaric acid (848 μg), rutin (336.5 μg), p-OH benzoic acid (76.5 μg), vanillic acid (65 μg), catechin (53.9 μg), caffeic acid (53.1 μg), protocatechuic acid (30.7 μg), and gallic acid (3.2 μg) per g sample [7]. There are also considerable investigations of the anticancer properties of these compounds in various types of cancer cells [23,24]. Studies examining the cytotoxic properties of extracts from various natural products show that the overall effect of the extract has first been examined, and the results have been attributed to synergistic effects. Effective compounds have been isolated from crude extract, and its biological effects have also been investigated [6]. It is believed that all these phenolic compounds of the P. vulgaris flower extract contribute to its cytotoxic effect.

5. Conclusion

This is the first study to examine the mechanisms involved in the in vitro cytotoxic effect of P. vulgaris flower extract on HeLa cells. Further studies are now needed for a more detailed understanding of the exact interaction of the signaling pathways involved.

Conflicts of interest

The authors declare that there are no conflicts of interest.

Acknowledgments

The authors wish to thank Professor Ersan Kalay from the Medical Biology Department, Karadeniz Technical University for professional assistance with the flow cytometry studies.

References

[1] S.A. Hussain, A.A. Sulaiman, C. Balch, et al., Natural polyphenols in cancer chemoprevention, Nutr. Cancer 68 (2016) 879–891.
[2] L. Tao, L. Han, X. Li, et al., Prevalence and risk factors for cervical neoplasia: a cervical cancer screening program in Beijing, BMC Public Health 14 (2014) 1185, http://dx.doi.org/10.1186/1471-2458-14-1185.
[3] S. Behzad, K. Ebrahim, M. Mosaddegh, et al., Primula auriculata extracts exert cytotoxic and apoptotic effects against HT-29 human colon adenocarcinoma cells, Iran. J. Pharm. Res. 15 (2016) 311–322.
[4] S. Unnati, S. Ripal, A. Sanjeev, et al., Novel anticancer agents from plant sources, Chin. J. Nat. Med. 11 (2013) 16–23.
[5] S. Demir, Y. Aliyazicioglu, I. Turan, et al., Antiproliferative and proapoptotic activity of Turkish propolis on human lung cancer cell line, Nutr. Cancer 68 (2016) 165–172.
[6] I. Turan, S. Demir, R. Aliyazicioglu, et al., Evaluation of antioxidant and cytoxic properties of Primula vulgaris leaf extract, ISU J. Nat. Sci. 20 (2017) 361–367.
[7] M.T. Ozkan, R. Aliyazicioglu, S. Demir, et al., Phenolic characterisation and antioxidant activity of Primula vulgaris and its antigenotoxic effect on fibroblast cells, Jundishapur J. Nat. Pharm. Prod. 12 (2017) e40073, http://dx.doi.org/10.5812/jnpzp.40073.
[8] F.A. Mostafa, M.A. Gamal, I.R.M. Sabrin, et al., Antioxidant and anti-inflammatory activities of phenolic constituents from Primula elatior L. aerial part, Int. J. Pharm. Pharm. Res. 6 (2014) 74–78.
[9] D.D. Orhan, B. Ozcelik, S. Hoshas, et al., Assessment of antioxidant, anti-bacterial, antimycobacterial, and antifungal activities of some plants used as folk remedies in Turkey against dermatophytes and yeast-like fungi, Turk. J. Biol. 36 (2012) 672–686.
[10] K. Aslam, I.A. Nawchoo, M.A. Bhat, et al., Ethno-pharmacological review of genus Primula, Int. J. Adv. Res. 2 (2014) 29–34.
[11] A.U. Turker, C. Usta, Biological screening of some Turkish medicinal plant extracts for antimicrobial and toxicity activities, Nat. Prod. Res. 22 (2008) 136–146.
[12] J. Jakubowicz-Gil, R. Paduch, Z. Ulz, et al., Cell death in HeLa cells upon im- peratorin and cisplatin treatment, Folia Histochem Cytobiol. 50 (2012) 381–391.
[13] T. Mosmann, Rapid colorimetric assay for cellular growth and survival: ap- plication to proliferation and cytotoxicity assays, J. Immunol. Methods 65 (1983) 55–63.
[14] I. Turan, S. Demir, K. Kiline, et al., Morus rubra extract induces G1 cell cycle arrest and apoptosis in human lung and prostate cancer cells, Ind. J. Pharm. Educ. Res. 51 (2017) 1185,http://dx.doi.org/10.5812/jnnpp.40073.
[15] S. Demir, I. Turan, Y. Aliyazicioglu, et al., Morus rubra extract induces cell cycle arrest and apoptosis in human colon cancer cells through endoplasmic re- ticulum stress and telomerase, Nutr. Cancer 69 (2017) 74–83.
[16] I. Turan, S. Demir, K. Kiline, et al., Antiproliferative and apoptotic effect of Morus nigra extract on human prostate cancer cells, Saudi Pharm. J. 25 (2017)
241–248.

[17] Q. Najmus-Saqib, F. Alam, M. Ahmad, Antimicrobial and cytotoxicity activities of the medicinal plant *Primula macrophylla*, J. Enzyme Inhib. Med. Chem. 24 (2009) 697–701.

[18] S. Behzad, A. Pirani, M. Mosaddegh, Cytotoxic activity of some medicinal plants from Hamedan district of Iran, Iran. J. Pharm. Res. 13 (2014) 199–205.

[19] Z. Amirghofran, M. Bahmani, A. Azadmehr, et al., Antitumor activity and apoptosis induction in human cancer cell lines by *Dionysia termeana*, Cancer Investig. 25 (2007) 550–554.

[20] F. Pehlivan Karakas, A. Birinci Yildirim, R. Bayram, et al., Antiproliferative activity of some medicinal plants on human breast and hepatocellular carcinoma cell lines and their phenolic contents, Trop. J. Pharm. Res. 14 (2015) 1787–1795.

[21] S.V. Tokalov, B. Kind, E. Wollenweber, et al., Biological effects of epicuticular flavonoids from *Primula denticulata* on human leukemia cells, J. Agric. Food Chem. 52 (2004) 239–245.

[22] M.L. Hu, Dietary polyphenols as antioxidants and anticancer agents: more questions than answers, Chang Gung Med. J. 34 (2011) 449–460.

[23] D. Ravishankar, A.K. Rajora, F. Greco, et al., Flavonoids as prospective compounds for anti-cancer therapy, Int. J. Biochem. Cell Biol. 45 (2013) 2821–2831.

[24] Y. Zhou, J. Zheng, Y. Li, et al., Natural polyphenols for prevention and treatment of cancer, Nutrients 8 (2016) 515, http://dx.doi.org/10.3390/nutrients8050515.